Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, APRIL 03, 2026 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES AN INVESTIGATION INTO ADMA BIOLOGICS, INC. (NASDAQ:ADMA) FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ADMA BIOLOGICS, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/ADMA-BIOLOGICS-CLASS-ACTION-LAWSUIT.

$ADMA STOCK NEWS: ADMA BIOLOGICS INVESTIGATED FOR SECURITIES FRAUD FOLLOWING CHANNEL STUFFING CLAIMS  INVESTORS NOTIFIED TO CONTACT BFA LAW

NEW YORK, APRIL 2, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADMA BIOLOGICS, INC. ("ADMA" OR THE "COMPANY") (NASDAQ: ADMA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ADMA BIOLOGICS, INC. - ADMA

NEW YORK--(BUSINESS WIRE)--THE LAW FIRM OF KIRBY MCINERNEY LLP CONTINUES ITS INVESTIGATION ON BEHALF OF ADMA BIOLOGICS, INC. (ADMA OR THE COMPANY) (NASDAQ:ADMA) INVESTORS CONCERNING THE COMPANY'S AND/OR MEMBERS OF ITS SENIOR MANAGEMENT'S POSSIBLE VIOLATION OF THE FEDERAL SECURITIES LAWS AND OTHER UNLAWFUL BUSINESS PRACTICES. [LEARN MORE ABOUT THE INVESTIGATION] WHAT HAPPENED? ON MARCH 24, 2026, CULPER RESEARCH PUBLISHED A REPORT ON ADMA ALLEGING CHANNEL STUFFING, AN UNDISCLOSED RELATED PAR.

ADMA INVESTOR ALERT: KIRBY MCINERNEY LLP INVESTIGATES POTENTIAL CLAIMS INVOLVING ADMA BIOLOGICS, INC.

BFA LAW IS INVESTIGATING ADMA BIOLOGICS AFTER ITS STOCK PLUMMETED 29% DUE TO CULPER RESEARCH CHANNEL STUFFING CLAIMS, POTENTIALLY VIOLATING FEDERAL SECURITIES LAWS. NEW YORK, MARCH 31, 2026 /PRNEWSWIRE/ -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES AN INVESTIGATION INTO ADMA BIOLOGICS, INC. (NASDAQ:ADMA) FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS.

ADMA SECURITIES NEWS: ADMA BIOLOGICS INVESTIGATED FOR SECURITIES FRAUD AFTER CULPER RESEARCH REPORT REVELATION SPARKS 29% STOCK DROP

NEW YORK, NEW YORK--(NEWSFILE CORP. - MARCH 27, 2026) - LEVI & KORSINSKY NOTIFIES INVESTORS THAT IT HAS COMMENCED AN INVESTIGATION INTO ADMA BIOLOGICS, INC. ("ADMA BIOLOGICS, INC.") (NASDAQ: ADMA) CONCERNING POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. ON THE Q4 2025 EARNINGS CALL, CEO ADAM GROSSMAN STATED "ASCENIV ACHIEVED $363 MILLION IN NET REVENUE, REPRESENTING 51% YEAR-OVER-YEAR GROWTH.

DID YOU SUFFER LOSSES IN ADMA BIOLOGICS, INC. (ADMA)? CONTACT LEVI & KORSINSKY ABOUT SECURITIES FRAUD CLAIMS

SHORT SELLER'S CHARACTERIZATION OF ASCENIV'S COMPETITIVE POSITION REFLECTS BLATANT MISUNDERSTANDING OF ADMA'S BUSINESS AND ITS ROLE AS LATE-LINE THERAPY FOR PATIENTS WHO ARE IMMUNE COMPROMISED AND THEREFORE, MAY NOT RESPOND TO VACCINES

ADMA BIOLOGICS ISSUES STATEMENT REFUTING UNSUBSTANTIATED, MISLEADING AND INACCURATE ALLEGATIONS BY CULPER RESEARCH

NEW YORK, MARCH 26, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADMA BIOLOGICS, INC. ("ADMA" OR THE "COMPANY") (NASDAQ: ADMA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

RAMSEY, N.J. AND BOCA RATON, FLA., MARCH 25, 2026 (GLOBE NEWSWIRE) -- ADMA BIOLOGICS, INC. (NASDAQ: ADMA) (ADMA OR THE COMPANY), A U.S. BASED, END-TO-END COMMERCIAL BIOPHARMACEUTICAL COMPANY DEDICATED TO MANUFACTURING, MARKETING AND DEVELOPING SPECIALTY BIOLOGICS, TODAY ADDRESSED A REPORT ISSUED ON MARCH 24, 2026 BY CULPER RESEARCH (THE SHORT REPORT), A FIRM THAT HAS PUBLISHED SIMILARLY NEGATIVE RESEARCH REPORTS REGARDING PUBLIC COMPANIES AFTER TAKING SHORT POSITIONS IN THE STOCK. THE SHORT REPORT DISCLOSES THAT CULPER RESEARCH HOLDS A SHORT POSITION IN ADMA. ADMA, AND ITS BOARD OF DIRECTORS TAKES SERIOUSLY ITS OBLIGATIONS TO FAIRLY AND ACCURATELY REPORT ITS OPERATING AND FINANCIAL RESULTS AND MAKE ALL PUBLIC DISCLOSURES IN ACCORDANCE WITH THE RULES AND REGULATIONS OF THE U.S. SECURITIES AND EXCHANGE COMMISSION AND IN ACCORDANCE WITH THE STANDARDS OF U.S. GAAP. THE SHORT REPORT, BY CONTRAST, APPEARS PREMISED ON SPECULATIVE ASSERTIONS DERIVED FROM UNIDENTIFIED AND UNRELIABLE SOURCES AND CONTAINS NUMEROUS MISLEADING, FALSE AND INACCURATE STATEMENTS. DESPITE THE CONJECTURE PERVADING THE SHORT REPORT, ADMA IS TAKING APPROPRIATE STEPS TO REVIEW THE ASSERTIONS.

ADMA BIOLOGICS ADDRESSES MISLEADING SHORT-SELLER REPORT

ADMA BIOLOGICS ANNOUNCES $125 MILLION ACCELERATED SHARE REPURCHASE WITH JPMORGAN AS PART OF A PLANNED $200 MILLION 2026 TOTAL SHARE REPURCHASE INITIATIVE

FY 2025 TOTAL REVENUE OF $510 MILLION, REPRESENTING 20% YEAR-OVER-YEAR GROWTH FY 2025 ASCENIV REVENUE GREW TO $363 MILLION, REPRESENTING 51% YEAR-OVER-YEAR GROWTH FY 2025 ADJUSTED NET INCOME( 1) OF $161 MILLION, REPRESENTING 35% YEAR-OVER-YEAR GROWTH FY 2025 ADJUSTED EBITDA( 2) OF $231 MILLION, REPRESENTING 40% YEAR-OVER-YEAR GROWTH INCOMING CFO APPOINTMENT EXPECTED TO FURTHER ENHANCE FINANCIAL STRATEGY, WORKING CAPITAL EXECUTION AND CAPITAL ALLOCATION DISCIPLINE ADVANCING SG-001 PIPELINE PROGRAM WITH ANTICIPATED FDA PRE-IND MEETING IN 2026; POTENTIAL ACCELERATED PATH TO REGISTRATIONAL TRIAL ONGOING SHARE REPURCHASES AND CAPITAL STRUCTURE TO INCREASE STOCKHOLDER VALUE REITERATING PREVIOUSLY PROVIDED 2026-2029 FINANCIAL GUIDANCE RAMSEY, N.J. AND BOCA RATON, FLA.

ADMA BIOLOGICS REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

ADMA BIOLOGICS TO REPORT FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ON FEBRUARY 25, 2026

FY 2025 PRELIMINARY UNAUDITED TOTAL REVENUE OF APPROXIMATELY $510511 MILLION MEETS OR EXCEEDS PRIOR GUIDANCE PREVIOUSLY PROVIDED FY 2025 ADJUSTED EBITDA(1) AND ADJUSTED NET INCOME(2) GUIDANCE REITERATED YEAR-END 2025 CASH GREW TO APPROXIMATELY $88 MILLION WITH AN UNAUDITED OPERATING CASH FLOW ESTIMATE OF ~$40 MILLION IN 4Q 2025 2026 EXPECTED TO BE ADMA'S FIRST FULL YEAR OF YIELD-ENHANCED PRODUCTION, SUPPORTING ANTICIPATED SUSTAINED MARGIN EXPANSION STRATEGIC PLASMA NETWORK REPOSITIONING EXPECTED TO ENHANCE MARGINS AND STRENGTHEN LONG-TERM SUPPLY VISIBILITY POSITIVE, STATISTICALLY SIGNIFICANT REAL-WORLD ASCENIV OUTCOMES TO BE PRESENTED AT CIS IN MAY 2026; ADDITIONAL ASCENIV DATA EXPECTED THROUGHOUT 2026 ADVANCING SG-001 PIPELINE PROGRAM WITH ANTICIPATED FDA PRE-IND SUBMISSION IN 2026 ONGOING SHARE REPURCHASES AND CAPITAL STRUCTURE STRENGTHENING TO ENHANCE STOCKHOLDER VALUE FY 2026 AND FY 2027 REVENUE EXPECTED TO BE APPROXIMATELY $635 MILLION AND $775 MILLION, RESPECTIVELY FY 2026 AND FY 2027 ADJUSTED NET INCOME EXPECTED TO BE APPROXIMATELY $255 MILLION AND $315 MILLION, RESPECTIVELY FY 2026 AND FY 2027 ADJUSTED EBITDA EXPECTED TO BE APPROXIMATELY $360 MILLION AND $455 MILLION, RESPECTIVELY ADMA TARGETS GREATER THAN $1.1 BILLION IN ANNUAL REVENUE IN FY 2029, REPRESENTING ~20% CAGR(3) ADMA TARGETS GREATER THAN $700 MILLION IN ADJUSTED EBITDA IN FY 2029, REPRESENTING ~30% CAGR RAMSEY, N.J. AND BOCA RATON, FLA.

ADMA BIOLOGICS ANNOUNCES PRELIMINARY FULL YEAR 2025 UNAUDITED TOTAL REVENUE AND PROVIDES BUSINESS UPDATE

RAMSEY, N.J. AND BOCA RATON, FLA., JAN. 05, 2026 (GLOBE NEWSWIRE) -- ADMA BIOLOGICS, INC. (NASDAQ: ADMA) (ADMA OR THE COMPANY), A U.S.-BASED, END-TO-END COMMERCIAL BIOPHARMACEUTICAL COMPANY DEDICATED TO MANUFACTURING, MARKETING, AND DEVELOPING SPECIALTY BIOLOGICS, TODAY ANNOUNCED THAT ADAM GROSSMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A PODIUM PRESENTATION AT THE J.P. MORGAN HEALTHCARE CONFERENCE ON MONDAY, JANUARY 12, 2026, AT 9:45 A.M. PT.

ADMA BIOLOGICS TO PRESENT AT THE J.P. MORGAN HEALTHCARE CONFERENCE ON JANUARY 12, 2026

3Q 2025 TOTAL REVENUE OF $134.2 MILLION, A 12% YOY INCREASE 3Q 2025 GAAP NET INCOME OF $36.4 MILLION, A 1% YOY INCREASE 3Q 2025 ADJUSTED EBITDA (1) OF $58.7 MILLION, A 29% YOY INCREASE 3Q 2025 ADJUSTED NET INCOME (2) OF $38.9 MILLION, AN 8% YOY INCREASE FDA LOT RELEASE OF FIRST YIELD-ENHANCED PRODUCTION BATCHES POSITIONS ADMA FOR MARGIN EXPANSION BEGINNING IN 4Q 2025 AND CONTINUING THROUGH 2026 POSITIVE, STATISTICALLY SIGNIFICANT REAL-WORLD HEALTH OUTCOMES DEMONSTRATED FOR ASCENIV RECORD ASCENIV DEMAND AND ANTICIPATED 2026 PAYER COVERAGE EXPANSION SUPPORT SUSTAINED AND ACCELERATING REVENUE GROWTH TRAJECTORY ADVANCING SG-001 PIPELINE PROGRAM AND CNPV VOUCHER APPLICATION SUBMITTED; STRENGTHEN LONG-TERM PIPELINE OUTLOOK ONGOING SHARE REPURCHASES AND STRENGTHENED CAPITAL STRUCTURE SUPPORT LONG-TERM STOCKHOLDER VALUE CREATION RAISING FY 2025 TOTAL REVENUE GUIDANCE TO $510 MILLION OR MORE AND FY 2026 TOTAL REVENUE GUIDANCE TO $630 MILLION OR MORE REAFFIRMING FY 2025 ADJUSTED EBITDA GUIDANCE OF $235 MILLION AND RAISING FY 2026 ADJUSTED EBITDA GUIDANCE TO $355 MILLION REVISING FY 2025 ADJUSTED NET INCOME GUIDANCE TO APPROXIMATELY $158 MILLION TO REFLECT A HIGHER EFFECTIVE TAX RATE AND RAISING FY 2026 ADJUSTED NET INCOME GUIDANCE TO MORE THAN $255 MILLION PROJECTING TOTAL ANNUAL REVENUE TO EXCEED $1.1 BILLION IN FY 2029 WITH ANTICIPATED OUTSIZED EARNINGS GROWTH AND OPERATIONAL MOMENTUM FROM CURRENT MARGIN LEVELS RAMSEY, N.J. AND BOCA RATON, FLA.

ADMA Biologics, Inc.

ADMA

Price

Financial Reports

No items found.

Press Releases

ADMA Biologics, Inc.

ADMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ADMA